Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Cost of Revenue (2019 - 2025)

Historic Cost of Revenue for Catalyst Pharmaceuticals (CPRX) over the last 7 years, with Q3 2025 value amounting to $22.7 million.

  • Catalyst Pharmaceuticals' Cost of Revenue rose 1751.83% to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.8 million, marking a year-over-year increase of 3144.05%. This contributed to the annual value of $68.8 million for FY2024, which is 3247.83% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Cost of Revenue of $22.7 million as of Q3 2025, which was up 1751.83% from $20.6 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Cost of Revenue ranged from a high of $22.7 million in Q3 2025 and a low of $4.5 million during Q2 2021
  • In the last 5 years, Catalyst Pharmaceuticals' Cost of Revenue had a median value of $12.0 million in 2023 and averaged $12.5 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first surged by 978.26% in 2021, then skyrocketed by 8201.51% in 2022.
  • Catalyst Pharmaceuticals' Cost of Revenue (Quarter) stood at $7.3 million in 2021, then soared by 52.35% to $11.2 million in 2022, then skyrocketed by 41.21% to $15.8 million in 2023, then skyrocketed by 36.9% to $21.6 million in 2024, then rose by 4.67% to $22.7 million in 2025.
  • Its last three reported values are $22.7 million in Q3 2025, $20.6 million for Q2 2025, and $17.9 million during Q1 2025.